Paradigm Biopharmaceuticals Ltd. announced recruitment of all clinical trial subjects (n=40) is complete. The company provided an update on its Phase 2a clinical trial in Lund, Sweden. The Phase 2a clinical trial is an allergen challenge study in subjects with allergic rhinitis (hay fever). It is a double blind, placebo controlled, cross over clinical trial design being conducted in 40 subjects. The first group of 15 clinical trial subjects will finish treatment in two weeks, the second group of 15 clinical trial subjects will finish treatment by mid-March, and the third group of 10 clinical trial subjects will finish treatment by end of March 2017. Last subject out of the study is scheduled for 31 March, 2017 with a readout of results anticipated in late Second Quarter or early Third Quarter Current year 2017. The company announced the progress of the Phase 2a clinical trial and it confirms the clinical trial is on schedule and on budget.